FDA questions benefits of testosterone therapy
This article was originally published in Scrip
Executive Summary
With the increasing use in the US of testosterone replacement therapies (TRTs), such as AbbVie's AndroGel, Auxilium's Testim, Lilly's Axiron and Endo's Fortesta, the FDA is reassessing the benefits those drugs provide, particularly in older men – a population for which regulators said the need "remains debatable."